Progression in Running Intensity or Running Volume and the Development of Specific Injuries in Recreational Runners: Run Clever, a Randomized Trial Using Competing Risks.

Runners and clinicians often assume that how training is progressed, by pushing intensity versus pushing distance, shapes which specific injury shows up, with faster, harder running thought to strain tendons like the Achilles and higher mileage thought to stress the knee. This trial tested that idea directly by randomizing 447 recreational runners to a 16-week schedule that progressively increased either high-intensity running or total running volume, following them for specific injury diagnoses. The result was that the two schedules did not differ in a statistically significant way for either the intensity-related injuries (Achilles tendinopathy, gastrocnemius injury, plantar fasciitis) or the volume-related injuries (patellofemoral pain, iliotibial band syndrome, patellar tendinopathy) at any of the four follow-up points measured. This is notable because it challenges a common assumption used to guide prevention advice.

The main limitation is that confidence intervals around these risk differences were wide, meaning the data cannot rule out meaningful differences in either direction, so this is a null finding under real uncertainty rather than proof that progression type has no effect.

If you run and have wondered whether increasing your pace and intensity versus increasing your weekly mileage puts you at risk for different types of injuries, this study offers some relevant information. Researchers randomly assigned over 400 recreational runners to follow a 16-week plan that either gradually added more high-intensity running or gradually added more total running distance, then tracked which injuries each group developed. The idea was that intensity-focused training might lead to injuries like Achilles tendon problems or plantar fasciitis, while volume-focused training might lead to knee-related injuries like patellofemoral pain.

But the study did not find a clear difference between the two groups for either type of injury at any point during the 16 weeks. This doesn't mean progression style makes no difference to injury risk, it means this trial's results were too uncertain to say one way or the other. The confidence ranges around the findings were wide, so a real difference either way can't be ruled out based on this study alone.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

This trial speaks to a question many clinicians face when counseling runners on injury prevention: should advice about tapering intensity versus volume be tailored to a runner's injury history, on the assumption that intensity progression drives tendon and calf-region injuries while volume progression drives patellofemoral and iliotibial band problems? The Run Clever trial tested this directly by randomizing 447 recreational runners to a schedule progressively increasing either high-intensity running (88% or more of maximal oxygen consumption) or total weekly volume over 16 weeks following an 8-week preconditioning period, with injuries confirmed by clinical examination rather than self-report. Of the 80 runners who sustained an injury (36 in the intensity-focused group, 44 in the volume-focused group), risk differences for hypothesized intensity-specific injuries and hypothesized volume-specific injuries were small and their 95% confidence intervals spanned zero at every assessed time point (2, 4, 8, and 16 weeks), so no statistically significant difference was detected between schedules for either injury category. This finding does not establish that training progression type is irrelevant to injury mechanism, only that this trial could not detect the hypothesized specific associations with the precision achieved; the wide confidence intervals leave open the possibility of true but undetected differences.

The abstract does not report on adverse events beyond the injury outcomes themselves, and the trial's etiology-level evidence (level 1b) informs but does not resolve clinical decisions about tailoring progression advice by injury type.